secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001599298-23-000074
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics Q2 net loss $14.7M; cash at $215M; HARMONi trials underway
------------------------------------------------------------------------------

- Net loss for Q2 2023 was $14.7M vs $16.8M YoY; six-month net loss $557.1M including $520.9M one-time IPR&D charge for ivonescimab license.
- Cash, equivalents, and short-term investments at June 30, 2023 totaled $215M, down from $648.6M at Dec 31, 2022; notes payable $100M due Sept 2024.
- First US patient dosed in Phase III HARMONi trial (ivonescimab + chemo in EGFR-mutant NSCLC); HARMONi-3 trial in first-line squamous NSCLC to begin H2 2023.
- Phase II data from Akeso's AK112-201 trial: median PFS 11 months, ORR 67% in first-line squamous NSCLC; presented at ASCO 2023.
- Collaboration license paid $500M upfront to Akeso; Akeso eligible for up to $4.5B in milestones plus low double-digit royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000074/0001599298-23-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000074/smmt-20230809.htm
  HTML page:      https://secwatch.observer/filing/0001599298-23-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer